1	Reversal of pathogen induced barrier defects in intestinal epithelial cells by contra-
2	pathogenicity agents
3	
4	Naheed Choudhry [*] , Flora Scott [*] , Meghan Edgar [†] , Gareth J Sanger ^{*†} , Paul Kelly [*]
5	
6	* Barts & The London School of Medicine, Queen Mary, University of London, London E1
7	2AT, UK.
8	⁺ Takeda California, Inc. Gastroenterology Drug Discovery Unit, 10410 Science Center Drive,
9	San Diego, California 92121
10	
11	
12	
13	
14	
15	
16	Corresponding author:
17	Dr Naheed Choudhry PhD
18	Barts & The London School of Medicine,
19	Queen Mary, University of London,
20	London E1 2AT, UK
21	Email: n.choudhry@qmul.ac.uk
22	Tel: 020 7882 7205

23 **Conflict of Interest Statement:**

24

25 All authors declare that there are no conflicting interests.

- Funding for this study was from Bart's Charity and provided support in the form of
 salaries for authors [NC] but did not have any additional role in the study design, data
 collection and analysis, decision to publish, or preparation of the manuscript.
- 2. ME is an employee of Takeda Pharmaceuticals This funder provided support in the
 form of salaries for authors [ME] but did not have any additional role in the study
 design, data collection and analysis, decision to publish, or preparation of the
 manuscript.
- 3. GJS is currently in receipt of funding from Takeda Pharmaceuticals, BBSRC together 34 with 31, Benevolent and the Dunhill Foundation. He acts as a scientific advisor to 3 35 Takeda Pharmaceuticals and Zealand Pharma. "These funders provided support in the 36 form of salaries for authors [GJS] but did not have any additional role in the study 37 design, data collection and analysis, decision to publish, or preparation of the 38 manuscript.
- 39
- 40
- 41

42 Abstract

Background: Environmental enteropathy (EE) is associated with stunting, impairment of responses to oral vaccines and other adverse health consequences in young children throughout the developing world. EE is characterised by chronic low-grade intestinal inflammation and disrupted epithelial-barrier integrity, partly resulting from dysregulation of tight junction proteins; observed in other enteropathies such as coeliac disease. During EE, this dysregulation of tight junction expression amplifies translocation of pathogenic bacteria across the intestinal mucosa.

Aims: Determine if enteropathogen-mediated epithelial-barrier failure can be ameliorated using
 contra-pathogenicity therapies.

52 **Methods:** Intestinal epithelial-barrier damage was assessed in Caco-2 cells incubated with three 53 important enteropathogens identified in EE patients: Enteropathogenic *Escherichia coli* (EPEC), 54 *Citrobacter rodentium* (*C. rodentium*) and *Cryptosporidium parvum* (*C. parvum*). Potential 55 therapeutic molecules were tested to detect effects on transepithelial resistance (TER), bacterial 56 translocation (BT), claudin-4 expression and regulation of the inflammatory cytokine response.

57 Results: All three enteropathogens compared to uninfected cells, reduced TER (EPEC; p<0.0001, 58 C. rodentium; p<0.0001, C. parvum; p<0.0007), reduced claudin-4 expression, and permitted BT 59 (EPEC; p<0.0001, C. rodentium; p<0.0001, C. parvum; p<0.0003) through the monolayer. Zinc, 60 colostrum, epidermal growth factor, trefoil factor 3, resistin-like molecule- β , hydrocortisone and 61 myosin-light inhibitor ML7 the chain kinase (MLCK) (Hexahydro-1-[(5-iodo-1-62 naphthalenyl)sulfonyl]-1H-1,4-diazepine hydrochloride); ML7) improved TER (up to 70%) and 63 decreased BT (as much as 96%). Only Zinc demonstrated modest antimicrobial activity.

64 **Conclusion:** The enteropathogens impaired intestinal-epithelial barrier-integrity with 65 dysregulation of claudin-4 and increased bacterial translocation. Enteropathogen-mediated

66 damage was reduced using contra-pathogenicity agents which mitigated the effects of pathogens

67 without direct antimicrobial activity.

68

- 69 Keywords: Intestinal-barrier, claudin-4, microbial translocation, Enteropathogenic Escherichia
- 70 coli, Citrobacter rodentium, Cryptosporidium parvum.

72 Introduction

Many disorders of the small intestine are characterised by increased permeability and impaired 73 barrier function^[1]. Environmental enteropathy (EE) is emerging as an example of a small intestinal 74 disorder induced by frequent, often co-existent, sub-clinical intestinal infections ^[2,3,4], with or 75 76 without nutrient deficiencies. It is associated with stunting and poor growth in young children 77 throughout the developing world^[5], with severe impaired responses to oral vaccines ^[6], and with reduced net absorption of micronutrients^[7] and some drugs ^[8]. EE is characterised by chronic 78 low-grade intestinal inflammation ^[9] such as lymphocytic infiltration of the lamina propria and 79 80 increased intraepithelial lymphocytes, increased translocation of bacteria across the intestinal mucosa^[10], reduced epithelial surface area, and immaturity of the absorptive cells of the 81 82 intestine. There is also dysregulation of tight junctions (TJ) located at the apical margins of the 83 lateral membranes of intestinal epithelial cells, which seal the intercellular space and define the 84 boundary of the host versus the environment in the intestinal lumen ^[11]. As this dysregulation appears, at least partly, to explain microbial translocation ^[10,11], characterisation of its 85 86 mechanisms is critical for improving health of children in low- and middle-income countries (LMICs)^[12]. It may also assist in understanding critical care sepsis, autoimmune and neurological 87 88 disorders of the gut.

89

90 Recent major studies, building on decades of observational microbiology, have defined many of 91 the most important enteropathogens responsible for diarrhoea in children in LMICs ^[13,14]. Our 92 understanding of the contribution of enteropathogens to EE is less advanced, but emerging 93 evidence links the severity of enteropathy (and growth failure) to frequent sub-clinical infections 94 with parasites, viruses and bacteria ^[2,15,16]. Those enteropathogens which are invasive or cause 95 intestinal epithelial disruption have been associated with more severe inflammation and growth

96 impairment^[17]. The mechanism through which enteropathogens induce enteropathy is unknown, 97 but in view of the intense microbial translocation found in children and adults with EE, it seems 98 that impairment of epithelial barrier function ^[1] is central to pathophysiology. Whether this 99 impairment is due to impairment of TJ, or to larger defects at sites of epithelial cell shedding, is 100 unclear. What is known is that shedding of individual intestinal epithelial cells does not lead to 101 impairment of epithelial barrier function ^[18], but simultaneous loss of multiple cells does impair 102 it and may lead to intestinal inflammation.

103

104 In previous work, our group studied adults with EE in Lusaka, Zambia using several methods 105 including histology and confocal laser endomicroscopy (CLE). We demonstrated that there was 106 marked epithelial barrier disruption in these EE patients with corresponding epithelial leakage 107 images visible by CLE ^[10]. We suggested the epithelial defects were probably sites of bacterial 108 translocation, and then hypothesised that it might be possible to ameliorate enteropathogen-109 mediated damage using therapies targeting the epithelium. Here we describe a series of 110 experiments to test novel therapeutic approaches for reduction of translocation in EE. These 111 agents were selected from transcriptomic work (Kelly, unpublished observations) and extensive 112 literature searches looking at their potential to function as either TJ modifiers or selective 113 enhancers of epithelial barrier function (full explanations are listed in Supplementary Table 1).

114

We used an *in vitro* modelling system with polarised Caco-2 cells and three different enteropathogens: 1) Enteropathogenic *Escherichia coli* (EPEC), part of a group of related pathogens which are an important cause of infant diarrhoea ^[19] and known to disrupt cell-cell junctions ^[20,21]; 2) *Citrobacter rodentium (C. rodentium),* a natural murine intestinal pathogen which has also been identified in EE cases of adults (human) in Zambia ^[22], and *Cryptosporidium*

120 parvum (C. parvum), associated with adverse outcomes in children with malnutrition ^[14,23]. C. 121 rodentium possesses a locus of enterocyte effacement (LEE) pathogenicity island that shares all 41 open reading frames with that of EPEC ^[24]. Therefore, EPEC and *C. rodentium* share a core set 122 123 of virulence factors utilising intimate bacterial attachment to the host cells through attaching and effacing (A/E) lesions ^[25,26]. C. parvum infects the intestinal epithelium producing a 124 125 parasitophorous vacuole in which the parasite resides in an intracellular yet extra-cytoplasmic 126 manner ^[23]. Cryptosporidial enteropathy has recently also been shown to occur in an animal 127 model ^[27].

128

129 Materials and Methods

130

131 Cell culture

132 The human Caco-2 enterocyte cell line (passage 6-40) was obtained from the American Type 133 Culture Collection (ATCC: HTB-37; Middlesex, UK) and grown as monolayers (VWR, Leicestershire, 134 UK) at 37°C in humidified 5% CO₂ in complete medium consisting of Dulbecco's Modified Essential 135 Medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 4 mM L-glutamine, 136 100U/ml penicillin, 100µg/ml streptomycin and 1% non-essential amino acids (Invitrogen Life 137 Technologies, Paisley, UK). For membrane integrity and translocation investigations, trypsinised 138 cells were seeded at a density of 1x 10⁶/ml into 12 well plates holding polyethylene terephthalate 139 (3.0µm) cell culture inserts (Transwell inserts, Millipore, Hertfordshire, UK), for 140 immunofluorescence experiments at 5x 10⁵/ml into 24-well culture plates (VWR International, 141 Leicestershire, UK) with 13mm glass coverslips, or at 2×10^6 /ml into 6 well plates for Western 142 blot experiments. Cells were grown until polarization (15-21 days) for translocation studies or 143 until 75% confluent for staining experiments (4-5 days; limiting cell damage during staining procedure) before experiments were conducted. In some experiments, FCS was withheld from the medium to model nutrient depletion in malnutrition. Formation and disruption of polarised monolayers (membrane integrity) was determined by regular measurement of transepithelial electrical resistance (TER) (Millicell-ERS; Millipore, Livingston, UK). Caco2 cell monolayers were considered polarised when TER readings reached 800-1000 ohms/cm²^[28] correlating with the upregulated expression of the brush border enzyme sucrase isomaltase (data not shown). Migration of Caco2 cells through the filters was not observed in basolateral media.

151

152 Bacterial strains and Parasite

153 EPEC strain RDEC-1 serotype O15:H7 (ATCC 49106; rabbit) and C. rodentium strain DBS100, 154 Biotype 4280 (ATCC 51459) were used. A non-pathogenic Escherichia coli K12 (E. coli K12) isolate 155 was a generous gift from Dr David Wareham (Blizard Institute, Barts and The London School of 156 Medicine, UK). Fresh colonies were stored on Luria-Bertani (LB) agar at 4°C and grown up in LB 157 broth (LB agar and broth; Fisher Scientific, Leicestershire, UK) at 37°C overnight for each 158 experiment. For immunofluorescence experiments, bacteria were incubated with rhodamine B 159 isothiocyanate (Sigma-Aldrich, Dorset, UK) at 1mg/ml for 2h in the dark with gentle shaking, then 160 washed. Oocysts of the C. parvum IOWA isolate (Bunch Grass Farm, Deary, ID, USA) were stored 161 in phosphate buffered saline (PBS) at pH7.2 at 4°C. Prior to use oocysts were surface sterilized in 162 10% (v/v) sodium hypochlorite (VWR, Leicestershire, UK) and centrifuged at 500xg for 10 min.

163

164 In vitro bacterial and parasite infections

Before infection commenced, monolayers were washed with PBS. Pathogens at 1x10⁶ colony forming units (CFUs)/well (for 12 well plates) were then added to the brush border face of the monolayer in 1ml complete medium. *C. parvum* infection was initiated using 1x10⁶ oocysts in 168 250µl complete medium with 1x10⁶ CFU/ml/well of non-pathogenic *E. coli* K12. After 2h at 37°C, 169 cells were washed to remove oocyst debris and 1ml complete medium with 1x10⁶ CFU/ml/well 170 of *E. coli* K12 introduced. Both bacterial and parasite infections developed for 24h without 171 antibiotics at any stage. For studies using 6- and 24-well plates the numbers of bacteria, parasites 172 and volumes of medium were scaled up or down accordingly.

173

174 Quantification of transepithelial resistance (TER) and bacterial translocation

175 Electrical resistance across the stratified epithelium was measured using a Millicell-ERS-2 176 instrument (Millipore, Bedford, Mass) with tweezer-like electrodes. Before measurement, the 177 electrodes were equilibrated and sterilized according to the manufacturer's recommendations. 178 The value obtained from a blank insert (with culture medium) was subtracted to give the net 179 sample resistance, which was then multiplied by the membrane area to give the resistance in 180 area-corrected units (Ω /cm²). TER was measured before and after 24h infections. To observe 181 bacterial translocation (BT), the medium from the basolateral compartment of the Transwell 182 insert after infection was cultured for colony quantification. The apicomplexan parasite, C. 183 parvum, was co-cultured with the non-invasive bacteria Escherichia coli K12 (K12) in the in vitro 184 model, Therefore, K12 was used as a marker of BT during C. parvum infection. Whereas, for EPEC 185 and *C. rodentium* experiments, each bacterium was used as the BT marker

186

187 Fixation of cell monolayers and Immunofluorescence (IF)

Confluent monolayers were fixed for 20min in 4% paraformaldehyde (Room temperature; RT), washed in PBS, then heated at 95°C for 10min with antigen retrieval buffer (10mM Tris Base, 1mM EDTA, 0.05% Tween, pH 9.5) and washed again in PBS. *C. parvum* infected cells were permeabilized with 0.2% Triton X-100 at RT for 3 min then washed in PBS. Cells were blocked 192 with 20% goat serum (Abcam, Cambridge, UK) for 30min, incubated with 1:100 rabbit polyclonal 193 anti-claudin 4 (antibodies from Abcam, Cambridge, UK) in 20% goat serum for 2h at RT, then 194 washed in PBS and incubated with conjugated secondary antibody (anti-rabbit IgG H & L -195 AlexaFluor) for 1h at RT. Cells were mounted in Vectorshield including DAPI (Vector Laboratories, Peterborough, UK). For C. parvum staining, 1µg/ml-1 VVL (lectin of Vicia villosa, Vector 196 197 laboratories, Peterborough, UK) in PBS with 1% Bovine serum albumin (BSA) was added to cells 198 for 1h at RT, washed and incubated with 1µg/ml conjugated streptavidin CY3. After 10min, cells 199 were mounted with vectorshield and DAPI. A Leica DM5000 upright epifluorescence microscope 200 was used for images at 400x magnification. A Zeiss LSM710 point scanning confocal microscopy 201 was used for representative confocal images at 400x magnification.

202

203 Lactate Dehydrogenase (LDH) Assay

204 To evaluate the extent of intestinal epithelial cell damage after enteropathogen infection, the

205 LDH assay (Promega, Southampton, UK) was performed on culture medium from cell monolayers

206 ± infection (24h), and analysed according to the manufacturer's instructions.

207

208 Pharmacological therapies

209 The potential therapeutic agents optimised and tested are listed in Table 1, and the rationale for

their selection is tabulated in Supplementary Table 1.

211

212 Antimicrobial Assay

213 To establish the antimicrobial activity of each molecule on the bacteria, EPEC, C. rodentium and

E. coli K12 was grown overnight in LB broth, washed and 1x10⁶ CFU/ml incubated with a molecule

at optimal testing concentrations for 24h at 37°C. *E. coli* K12 was co-incubated with *C. parvum*.

After the incubation period, the samples were cultured on LB agar and bacterial coloniesenumerated.

218

219 Western blotting

220 Proteins for western blotting were extracted using lysis buffer (Cell RIPA lysis plus protease 221 inhibitor cocktail, Sigma-Aldrich, Dorset, UK) and sonicated (100W, 10s; Microson, New York, 222 USA), then centrifuged (13000xg, 10min, 4°C). Total protein (20µg) was boiled at 95-100°C for 5 223 min, cooled on ice before electrophoresis on 12% SDS-Tris-Glycine gels and then transferred to a 224 Polyvinylidene fluoride (PVDF) membrane (Amersham Biosciences, Bucks, UK). After overnight 225 rabbit polyclonal claudin-4 Ab (1:1000) incubation (4°C), the membrane was washed repeatedly 226 in tris-buffer saline (TBS) and then incubated for 1h with horseradish peroxidase (HRP; 1:10; 227 Supersignal West Pico rabbit kit (Pierce Fast; Thermo Scientific, Loughborough). Recombinant 228 human claudin-4 was used as a positive control. To confirm equal protein loading, the membrane 229 was stripped and Re-Blot plus strong solution (Millipore, Livingston, UK) was added for 20min. 230 After washes in TBS, the membrane was incubated at 4°C with anti-human GAPDH (1:5000 231 dilution, Sigma-Aldrich, Dorset, UK) for 1hr and re-developed.

232

233 Cytokine and Chemokine expression assay (Takeda)

234 Cell supernatants were assessed for cytokine and chemokine expression using the V-PLEX pro-235 inflammatory panel 1 human assay (Meso Scale Discovery MD, USA). The assay was performed 236 according to the manufacturer's instruction.

237

238 Data analysis

239 TER is presented without transformation whilst bacterial translocation is presented as log colony-

forming units/ml. TER % change was calculated by using the mean decrease due to each enteropathogen. The Wilcoxon signed-rank test was used to test the effect of the intervention on paired data from each experiment conducted on adjacent wells, with or without the therapy. One-way ANOVA with Kruskal-Wallis/Tukey's post hoc was used for antimicrobial activity, LDH, bacterial invasion and adherence experiments and cytokine analysis where appropriate. Statistical significance was established at p<0.05.

246

- 248 Results
- 249

250 Selected pathogens induce barrier dysfunction in Caco2 cell

251 In preliminary experiments, an appropriate TER (Ω/cm^2) was selected for Caco2 cells to confirm 252 polarity, which correlated with the expression of the bush border enzyme sucrase isomaltase 253 (data not shown). All three enteropathogens reduced TER irrespective of nutrient rich or nutrient 254 deplete conditions (Figure 1A). Both bacterial pathogens elicited a greater decline in TER than C. 255 parvum whilst non-pathogenic E. coli K12 alone did not modify the TER readings. EPEC and C. 256 rodentium added to the apical sides of the intestinal monolayer were isolated and cultured from 257 the basal Transwell chamber signifying bacterial translocation (BT) had occurred across the 258 epithelium (Figure 1B). Consistent with observations of TER, there was no BT during incubation 259 of *E. coli* K12 alone in the *in vitro* model, but this was induced by co-culture with *C. parvum*.

260

261 To confirm that human Caco2 cells were infected by C. rodentium (murine; DBS100), EPEC (rabbit; 262 RDEC-1) and *C. parvum* + *E. coli* K12 (human; K12), adherence and invasion (gentamicin) assays 263 were performed (Supplementary Figure 1A and B). Previous studies have reported that both 264 animal and human EPEC strains are clonally related ^[29], and regardless of the isolate's original host, colonisation is similar and so not host dependent ^[30]. This study has confirmed those key 265 266 observations by demonstrating the ability of EPEC (RDEC-1) to attach to the human intestinal 267 epithelial cells from 30min onwards (P<0.05; Supplementary Figure 1A) and were isolated from 268 inside Caco2 cells after 60min (P<0.05; Supplementary Figure 1B). The murine pathogen C. 269 rodentium, also infected Caco2 cells but took longer to attach (60min) and were isolated from 270 within the cell monolayer at 120min. E. coli K12 when co-cultured with C. parvum, attached and 271 were isolated from within Caco2 cells over a similar timescale to C. rodentium but in much lower 272 numbers. The results confirmed the pathogenicity of the three enteropathogens in Caco2 cells

and indicated that C. parvum may induce paracellular translocation of E. coli K12 whilst EPEC and

274 *C. rodentium* appeared to demonstrate partial transcellular movement.

275

276 Barrier dysfunction was associated with reduced claudin-4

Our group has previously shown dysregulation of claudin-4 in biopsies from adults and children 277 with EE ^[10,31]. To establish if enteropathogen-induced barrier disruption was also accompanied 278 279 by impairment of claudin-4 expression, immunofluorescence and Western blotting of the protein 280 was performed. In monolayers infected with either of the three enteropathogens, the expression 281 of claudin-4 (green) was reduced (Figure 2A and B), and this was confirmed by Western blotting 282 (Figure 2C) and densitometry (Figure 2D). Interestingly, unlike EPEC and *C. parvum* infections, at 283 the site of *C. rodentium* infection the claudin-4 protein appeared to aggregate around the 284 bacterium, with reduced expression over the remaining cells in the monolayer (Figure 2A). 285 Although, the LDH assay showed a small increase in Caco2 cell lysis after enteropathogen-286 infection this was not statistically significant compared to non-infected controls and therefore is 287 unlikely to explain the loss of claudin-4 expression (Figure 2D). Consistent with TER findings 288 (Figure 1A), the results show bacterial infections elicited greater reductions of claudin-4 than C. 289 parvum infection.

290

291 Partial reversal of pathogen-induced barrier dysfunction using contra-pathogenicity agents

292 Several molecules were screened for their ability to limit the enteropathogen-induced damage 293 caused to the epithelial barrier integrity (Table 1 and Supplementary table 1). Seven of these 294 agents: zinc, colostrum, human epidermal growth factor (hEGF), trefoil factor-3 (TFF3), resistin-295 like molecule-beta (RELM-β), hydrocortisone and the myosin-like chain kinase (MLCK) inhibitor 296 ML7 (Hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine-hydrochloride); ML7),

297 impeded the pathogen-induced decrease in TER (Figure 3A) and they also reduced BT (Figure 3B), 298 suggesting a relationship between these two processes. Vitamin A and leptin had minimal effect 299 on pathogen-induced damage. Interestingly, to determine the dependence of the molecules on 300 nutrients, Caco2 cells were starved of fetal calf serum (FCS) which crudely mimics clinical 301 malnutrition. Nutrient-rich conditions improved TER readings in cells treated with, TFF3, 302 hydrocortisone, hEGF, zinc and ML7. Colostrum, ML7 (in C. parvum only) and Relm- β , had a 303 greater effect in nutrient-deplete conditions. To determine whether the nine molecules acted on 304 the enteropathogens in an antimicrobial manner we incubated these molecules directly with the 305 pathogens, and no antimicrobial activity was observed except with zinc (Figure 4). Tissue inhibitor 306 of metalloproteinases (TIMP) 1 and 2 were tested along with low minimum inhibitory 307 concentrations (MICs) of tetracycline and doxycycline (known to also function as 308 metalloproteinase inhibitors). However, data are not included due to the strong antimicrobial 309 activity observed with these widely used antibiotics.

310

311 Two of the most effective contra-pathogenic agents TFF3 and ML7, were further evaluated by 312 investigating their effect on expression of claudin-4. Both molecules ameliorated the pathogen-313 induced reduction of claudin-4 protein expression (Figure 5A and C). The Western blot results 314 were confirmed by densitometry (Figure 5B and D), correlating with observations that both 315 molecules decreased LDH release from cells induced by enteropathogens infections (Figure 5E). 316 Although the LDH readings after infection from either of the three enteropathogens was already 317 low (Figure 2E and Figure 5E), ML7 appeared to block LDH release completely from the three 318 enteropathogen-infected Caco2 cells (p<0.0001). However, TFF3 appeared slightly more effective 319 in reducing LDH levels in EPEC-infected cells (p<0.0001) compared to C. rodentium (P<0.007) and

320 *C. parvum* (p<0.007) – infected monolayers.

321

A dose-response relationship was apparent for TFF3 (Figure 6), which was also dependent on nutrient availability. TFF3 increased TER and reduced BT in both nutrient-rich and nutrientdepleted conditions for both EPEC (Figure 6A and B,) and *C. rodentium* (Figure 6C and D). The concentration-dependence of TFF3 was clearer in *C. rodentium* infection, and translocation was reduced further in the presence of FCS (Fig 6A and C) than in its absence (Fig 6B and D). The dose-response experiments also demonstrated the marked inverse correlation between TER and BT (EPEC: $\rho = -0.80$, P<0.0001; *C. rodentium*: $\rho = -0.66$, P<0.0001).

329

330 TFF3 and Relm-β increase immune-regulation in enterocytes

331 The disruption of intestinal barrier function and the alteration of the TJ protein claudin-4 332 following infection, led us to additionally examine the effect of two goblet cell released contra-333 pathogenic molecules, TFF3 and Relm-β, in regulating the inflammatory response. The effects of 334 TTF3 or Relm- β on cytokine release by enteropathogens in polarised Caco2 cells over 24h was 335 determined by measuring cytokines in supernatants by ELISA. TFF3 and Relm- β modestly 336 increased the induction of interleukin 10 (IL-10) and tumour necrosis factor alpha (TNF- α) by EPEC 337 (Figure 7). Relm- β also increased induction of IL-2 and IL-6 by all three pathogens and induced 338 these two cytokines in the absence of pathogens.

339

340 **Discussion**

341

342 Several investigators have shown that EPEC ^[32], *C. rodentium* ^[33] and *C. parvum* ^[34] infections of 343 intestinal epithelial monolayers alter barrier function. Using a similar *in vitro* model, we have tried 344 to model the epithelial barrier dysfunction in environmental enteropathy (EE) utilising these 345 important enteropathogens. We have demonstrated that all three pathogens reduced intestinal 346 epithelial integrity by decreasing TER associated with downregulation of claudin-4. This barrier 347 defect could be prevented by agents that mitigated pathogenic effects including the reduction of 348 bacterial translocation. We refer to this mechanism as a contra-pathogenicity effect as it occurs 349 without demonstrable antimicrobial activity (except for zinc) and therefore appears to alter the 350 balance between host and pathogen. There was a clear inverse correlation between membrane 351 integrity (TER) and BT although details of the mechanism(s) involved require further work. The 352 contra-pathogenicity effect seems to entail protection against cytopathic effects and tight junction 353 disruption and reduced ionic conductance.

354

355 The rabbit EPEC strain, RDEC-1, has extensively been used over the years to study the human EPEC 356 infection because it contains a homolog of the human EPEC 35kb LEE locus (locus of enterocyte 357 effacement), which encodes all necessary determinants for the (A/E) phenotype^[35]. Previous 358 studies have shown human and rabbit EPEC strains cause A/E lesions in infant pigs indicating EPEC colonisation is not host-dependent^[30] and supports our data. Sharing a genetically similar LEE 359 360 pathogenicity island is the pathogen C. rodentium; the causative agent of transmissible murine 361 colonic hyperplasia, a naturally occurring disease in laboratory mice ^[36]. The protozoan parasite *C*. *parvum* causes cryptosporidiosis^[37] and has been listed as one of the four major enteric pathogens 362 causing life-threatening diarrhoea in infants globally^[3,13]. Importantly, for our investigation all three 363 enteropathogens have been isolated in EE patients (both adults and children) in Zambia^[22,23,24] and 364 365 when used in our in vitro model have been shown to infect Caco2 cells (See supplementary Figure 366 1).

367

368 Previous in vitro studies have observed that EPEC-induced barrier dysfunction is attributed in part 369 to the secretion of the effector protein, EspF^[38] within the first 24hr of infection and not at later 370 time-points^[21]. The mechanism by which EspF expression disrupts the TJ barrier has been correlated with the redistribution of occludin^[38]. Our study now demonstrates the TJ protein, claudin-4, is also 371 372 affected within the first 24hr of EPEC infection. Other effector molecules such as EspG1 and EspG2 373 (involved in microtubule destruction) cause TJ perturbation but claudin-4 localisation has not been 374 shown to be affected^[39]. Unsurprising, *C. rodentium* also increased intestinal epithelial permeability 375 in our in vitro model which correlated with claudin-4 disruption. It has been previously reported 376 that claudin-4 expression was downregulated during C. rodentium infection of the murine cell line 377 CMT-93, due to the Rho-Rho kinase (ROCK) signalling pathway^[33]. However, this mechanism has 378 not been determined in our model. In agreement with our investigation, the third enteropathogen 379 tested, C. parvum has been shown to decrease protein levels of claudin-4 in Caco2 cells, mouse 380 enteroid-derived monolayers and the ileal and jejunal mucosa of mice post- 24hr infection^[37]. 381 Kumar et al., (2018) observed that in Caco2 cells the parasite had no effect on mRNA levels of 382 claudin-4, whereas both mRNA and protein levels were decreased in vivo (murine and enteroids) 383 models. This suggested posttranslational mechanisms, play a role in *C. parvum*-induced modulation 384 of claudin-4. Cell death would also reduce claudin-4 expression and increase bacterial translocation 385 although our lactate dehydrogenase assay findings (Figure 2E) demonstrated this was not a 386 significant factor.

387

Two of the agents we selected for testing (Figure 3) are micronutrients (Vitamin A and Zinc) which are well known to have protective or therapeutic effects in reducing diarrhoea incidence or severity^[40,41]. ML7 is a small molecule inhibitor of Myosin Light Chain Kinase (MLCK) which has been implicated in TJ remodelling^[42]. Leptin is a hormone postulated to have effects in intestinal 392 resistance to infection^[43]. Whilst, the remaining five are paracrine mediators of mucosal healing, or 393 nutrient solutions such as colostrum which are likely to contain them. Vitamin A and leptin had very 394 little effect at the concentrations and in the preparations used. Among the other active agents, there was considerable variation in nutrient dependence: hydrocortisone seems to have greater 395 396 efficacy under nutrient-deplete conditions, whereas colostrum, hEGF and TFF3 seem to be more 397 effective in nutrient replete states. Zinc deficiency is known to result in epithelial barrier leak in the 398 intestines and alter TJ composition^[44]. We found zinc improved TER readings and decreased BT. Its 399 effect on translocation was proportionately greater in C. parvum infection than in bacterial 400 infections (EPEC and C. rodentium). Interestingly, this effect was nutrient-independent. These 401 findings are in line with previous studies which showed zinc had a protective effect in pigs suffering 402 from enterotoxigenic Escherichia coli (ETEC) infections as zinc supplementation prevented or 403 alleviated diarrhoea in this model ^[45].

404

405 It appeared that the contra-pathogenicity agents tested varied in effect and this is likely to reflect 406 variation in cellular receptors or targets. Retinoids act through nuclear receptors. Whilst, Relm- β is 407 exclusively found in goblet cells of the intestines and may play a role during colonisation and infection of the gastrointestinal tract^[46]. It plays a role in the production of Th2 cytokines during 408 nematode infections in mice and is essential in helminth expulsion^[47]. Relm-β also has been shown 409 410 to be induced during *C. rodentium* infection, in which it is involved in recruiting CD4+ T-cells^[48]. TFF3 411 is also a goblet cell product with well-established protective effects on the small intestinal mucosa^[49] working at the cell membrane. ML7 acts on the adenosine triphosphate- binding site of 412 the active centre of MLCK causing inhibition^[42] and therefore will perform throughout the cell. The 413 414 agents which had the greatest effect on translocation, such as TFF3 and ML7, also reduced the 415 effect of pathogens on claudin-4 expression (Figure 5). With TFF3 demonstrating its action in a dose416 dependent manner (Figure 6).

417

418 Despite the absence of lymphoid cells in this model we were still able to detect low levels of 419 cytokine and chemokine secretion, except for IL-8 which was in the range reported by Sansonetti 420 et al., (1999). The significance of these immunological results is unclear at present. It is possible that 421 the enteropathogens disrupt claudin-4 distribution and inhibit its restoration and so the contra-422 pathogenicity molecules may act by modulating the inflammatory response preventing complete 423 claudin-4 obliteration. Further investigations are needed to understand the cytokine results and to 424 establish if these therapies involve dual actions, working on both the pathogen and by controlling 425 the release of the inflammatory mediators which if in excess could be detrimental to host health. 426 427 Given the emergence of antimicrobial resistance as a global phenomenon, development of 428 strategies to reduce the impact of pathogens on the host intestinal mucosa could be helpful. Some 429 of the agents we studied are in clinical use, could be easily applied to clinical studies or inserted 430 into clinical trials. 431

433 **References**

- 434 1. Turner JR. Intestinal mucosal barrier function in health and disease. Ann Rev Immunol 2009;
 435 9: 799-809.
- 2. Salazar-Lindo E, Allen S, Brewster DR, Elliott EJ, *et al.*, Intestinal infections and
 Environmental Enteropathy: Working Group Report of the Second World Congress of
 Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric
 Gastroenterology and Nutrition 2004; 39: S662–S669.
- 3. Platts-Mills JA, Babji S, Bodhidatta L, Gratz J, *et al.*, MAL-ED Network Investigators.
 Pathogen-specific burdens of community diarrhoea in developing countries: a multisite
 birth cohort study (MAL-ED). Lancet Glob Health. 2015 Sep;3(9)
- 443 4. Lee GO, McCormick BJJ, Seidman JC, Kosek MN, *et al.*, For The Mal-Ed Network
 444 Investigators. Infant Nutritional Status, Feeding Practices, Enteropathogen Exposure,
 445 Socioeconomic Status, and Illness Are Associated with Gut Barrier Function As Assessed by
 446 the Lactulose Mannitol Test in the MAL-ED Birth Cohort. Am J Trop Med Hyg. 2017
 447 Jul;97(1):281-290.
- 5. Prendergast A, Kelly P. Enteropathies in the developing world; neglected effects on global
 health. Am J Trop Med Hyg 2012; 86: 756-763.
- 450 6. Naylor C, Lu M, Haque R, Mondal D, *et al.*, PROVIDE study teams, Ma JZ, Petri WA Jr.
- 451 Environmental Enteropathy, oral vaccine failure and growth faltering in infants in 452 Bangladesh. EBioMedicine. 2015; 2: 1759-66.
- 453 7. Manary MJ, Abrams SA, Griffin IJ, Quimper MM, *et al.*, Perturbed zinc homeostasis in rural
- 454 3-5-y-old Malawian children is associated with abnormalities in intestinal permeability
- 455 attributed to tropical enteropathy. Pediatr Res. 2010 Jun;67(6):671-5.

8. Tostman A, Mtabho CM, Semvua HH, van den Boogaard J, *et al.*, Pharmacokinetics of firstline tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother 2013; 57:
3208-3213.

9. Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with
impaired small intestinal barrier function, leading to endotoxemia and systemic
inflammation. J Nutr 2003; 133: 1332–1338.

- 462 10. Kelly P, Besa E, Zyambo K, Louis-Auguste J *et al.*, Endomicroscopic and transcriptomic
 463 analysis of impaired barrier function and malabsorption in environmental enteropathy.
 464 PLoS Negl Trop Dis 2016; 10
- 465 11. Korpe PS, Petri WA. Environmental Enteropathy: critical implications of a poorly
 466 understood condition. Trends in Molecular Medicine 2012; 18: 328-336.
- 467 12. Prendergast AJ, Kelly P. Interactions between intestinal pathogens, enteropathy and
 468 malnutrition in developing countries. Curr Op Infect Dis 2016 Jun;29(3):229-36.

469 13. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, *et al.*, Burden and aetiology of diarrhoeal

470 disease in infants and young children in developing countries (the Global Enteric

471 Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382: 209–22.

472 14. Liu J, Platts-Mills JA, Juma J, Kabir F, et al., Use of quantitative molecular diagnostic

473 methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control

474 study. Lancet 2016; 388: 1291-301.

15. Lima AAM, Leite ÁM, Di Moura A, Lima NL, *et al.*, Determinant Variables, Enteric Pathogen

476 Burden, Gut Function and Immune-related Inflammatory Biomarkers Associated With

477 Childhood Malnutrition: A Prospective Case-Control Study in Northeastern Brazil. Pediatr

478 Infect Dis J. 2017 Dec;36(12):1177-1185.

479 16. Amour C, Gratz J, Mduma E, Svensen E, *et al.*, Etiology, Risk Factors, and Interactions of
480 Enteric Infections and Malnutrition and the Consequences for Child Health and
481 Development Project (MAL-ED) Network Investigators. Epidemiology and Impact of
482 Campylobacter Infection in Children in 8 Low-Resource Settings: Results From the MAL-ED
483 Study. Clin Infect Dis. 2016 Nov 1;63(9):1171-1179.

- 484 17. Kosek MN, and the MAL-ED Network Investigators. Causal Pathways from
 485 enteropathogens to Environmental Enteropathy: findings from the MAL-ED birth cohort
 486 study. e-Biomedicine 2017; in press.
- 487 18. Marchiando AM, Shen L, Graham WV, Edelblum KL, *et al.*, The epithelial barrier is
 488 maintained by in vivo tight junction expansion during pathologic intestinal epithelial
 489 shedding. Gastroenterology 2011; 140: 1208-1218.
- 490 19. Flynn AN, Buret AG. Caspases-3, -8, and -9 are required for induction of epithelial cell
 491 apoptosis by enteropathogenic E. coli but are dispensable for increased paracellular
 492 permeability. Microb Pathog. 2008 Apr;44(4):311-9. Epub 2007 Oct 24.
- 493 20. Tapia R, Kralicek SE, Hecht GA. Modulation of epithelial cell polarity by bacterial
 494 pathogens. Ann N Y Acad Sci. 2017 Oct;1405(1):16-24.
- 495 21. Shifflett DE, Clayburgh DR, Koutsouris A, Turner JR, Hecht GA. Enteropathogenic E. coli
 496 disrupts tight junction barrier function and structure in vivo. Lab Invest. 2005
 497 Oct;85(10):1308-24.
- 498 22. Kelly P, Menzies I, Crane R, Zulu I, *et al.*, Responses of small intestinal architecture and
 499 function over time to environmental factors in a tropical population. Am J Trop Med Hyg
 500 2004; 70: 412-419.

- 501 23. Amadi B, Mwiya M, Musuku J, Watuka A, et al., Effect of nitazoxanide on morbidity and
- 502 mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet.
 503 2002 Nov 2;360(9343):1375-80.
- 504 24. Deng W, Li Y, Vallance BA, Finlay BB. Locus of enterocyte effacement from Citrobacter
- 505 rodentium: sequence analysis and evidence for horizontal transfer among attaching and
- 506 effacing pathogens. Infect Immun. 2001 Oct;69(10):6323-35.
- 507 25. Lai Y, Rosenshine I, Leong JM, Frankel G. Intimate host attachment: enteropathogenic and
 508 enterohaemorrhagic Escherichia coli. Cell Microbiol. 2013 Nov;15(11):1796-808.
- 509 26. Yang J, Tauschek M, Hart E, Hartland EL, Robins-Browne RM. Virulence regulation in
- 510 Citrobacter rodentium: the art of timing. Microb Biotechnol. 2010 May;3(3):259-68.
- 511 27. Liu J, Bolick DT, Kolling GL, Fu Z, Guerrant RL. Protein malnutrition impairs intestinal
- epithelial cell turnover, a potential mechanism of increased cryptosporidiosis in a murine
 model. Infect Immun 2016; 84: 3542-3549.
- 514 28. Butler M, Ng CY, van Heel DA, Lombardi G, *et al.*, Modulation of dendritic cell phenotype
- and function in an in vitro model of the intestinal epithelium. Eur J Immunol. 2006
- 516 Apr;36(4):864-74.
- 517 29. Moura RA, Sircili MP, Leomil L, Matté MH, *et al.*, Clonal relationship among atypical
 518 enteropathogenic Escherichia coli strains isolated from different animal species and
 519 humans. Appl Environ Microbiol. 2009 Dec;75(23):7399-408
- 30. Moon HW, Whipp SC, Argenzio RA, Levine MM, Giannella RA. Attaching and effacing
 activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit
 intestines. Infect Immun. 1983 Sep;41(3):1340-51
- 523 31. Amadi B, Besa E, Zyambo K, Kaonga P, et al., Impaired Barrier Function and Autoantibody
- 524 Generation in Malnutrition Enteropathy in Zambia. EBioMedicine. 2017 Aug; 22:191-199

525 32. Shifflett DE, Clayburgh DR, Koutsouris A, Turner JR, Hecht GA. Enteropathogenic E. coli
526 disrupts tight junction barrier function and structure in vivo. Lab Invest. 2005
527 Oct;85(10):1308-24.

528 33. Flynn AN, Buret AG. Tight junctional disruption and apoptosis in an in vitro model of
529 Citrobacter rodentium infection. Microb Pathog. 2008 Aug;45(2):98-104.

34. de Sablet T, Potiron L, Marquis M, Bussière FI, Lacroix-Lamandé S, Laurent F.
Cryptosporidium parvum increases intestinal permeability through interaction with
epithelial cells and IL-1β and TNFα released by inflammatory monocytes. Cell Microbiol.
2016 Dec;18(12):1871-1880.

35. De Rycke J, Comtet E, Chalareng C, Boury M, Tasca C, Milon A. Escherichia coli O103 from
rabbit elicits actin stress fibers and focal adhesions in HeLa epithelial cells, cytopathic
effects that are linked to an analog of the locus of enterocyte effacement. Infect Immun.
1997 Jul;65(7):2555-63

538 36. Higgins LM, Frankel G, Douce G, Dougan G, MacDonald TT. Citrobacter rodentium infection

in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine

inflammatory bowel disease. Infect Immun. 1999 Jun;67(6):3031-9.

541 37. Kumar A, Chatterjee I, Anbazhagan AN, Jayawardena D, , *et al.*, Cryptosporidium parvum

542 disrupts intestinal epithelial barrier function via altering expression of key tight junction

and adherens junction proteins. Cell Microbiol. 2018 Jun;20(6)

544 38. McNamara BP, Koutsouris A, O'Connell CB, Nougayréde JP, Donnenberg MS, Hecht G.

545 Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal

barrier function. J Clin Invest. 2001 Mar;107(5):621-9.

- 547 39. Glotfelty LG, Zahs A, Hodges K, Shan K, Alto NM, Hecht GA. Enteropathogenic E. coli
 548 effectors EspG1/G2 disrupt microtubules, contribute to tight junction perturbation and
 549 inhibit restoration. Cell Microbiol. 2014 Dec;16(12):1767-83.
- 40. Aamer Imdad, Mohammad Yawar Yakoob, Christopher Sudfeld, Batool A Haider, Robert E
- 551 Black, Zulfiqar A Bhutta Impact of vitamin A supplementation on infant and childhood
- 552 mortality. BMC Public Health. 2011; 11(Suppl 3): S20.
- 41. Marzia Lazzerini, Humphrey Wanzira. Oral zinc for treating diarrhoea in children. Cochrane
 Database Syst Rev. 2016 Dec 20; (12)
- 42. Jerrold R. Turner, Mary M. Buschmann, Anne Sailer, Isabel Romero Calvo, Le Shen. The
- role of molecular remodeling in differential regulation of tight junction permeability. Semin
- 557 Cell Dev Biol. 2014 Dec; 0: 204–212
- 43. Chelsea S. Marie, Hans P. Verkerke, Shom N. Paul, Aaron J. Mackey, William A. Petri, Jr
 Leptin Protects Host Cells from Entamoeba histolytica Cytotoxicity by a STAT3-Dependent
- 560 Mechanism. Infect Immun. 2012 May; 80(5): 1934–1943.
- 561 44. Reeves PG, Briske-Anderson M, Johnson L. Pre-treatment of Caco-2 cells with zinc during
- the differentiation phase alters the kinetics of zinc uptake and transport (2). J Nutr
 Biochem. 2001 Dec;12(12):674-684.
- Metzler-Zebeli BU, Caine WR, McFall M, Miller B, *et al.*, Supplementation of diets for
 lactating sows with zinc amino acid complex and gastric nutriment-intubation of suckling
 pigs with zinc methionine on mineral status, intestinal morphology and bacterial
 translocation in lipopolysaccharide-challenged weaned pigs. J Anim Physiol Anim Nutr
 (Berl). 2010 Apr;94(2):237-49

46. Hogan SP, Seidu L, Blanchard C, Groschwitz K, *et al.*, Resistin-like molecule beta regulates
innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin

571 Immunol. 2006 Jul;118(1):257-68.

- 572 47. Herbert DR, Yang JQ, Hogan SP, Groschwitz K, et al., Intestinal epithelial cell secretion of
- 573 RELM-beta protects against gastrointestinal worm infection. J Exp Med. 2009 Dec 574 21;206(13):2947-57.
- 48. Bergstrom KS, Morampudi V, Chan JM, Bhinder G, *et al.*, Goblet Cell Derived RELM-β
 Recruits CD4+ T Cells during Infectious Colitis to Promote Protective Intestinal Epithelial
- 577 Cell Proliferation. PLoS Pathog. 2015 Aug 18;11(8)
- 578 49. Ting Fu, Eva B. Znalesniak, Thomas Kalinski, *et al.*, TFF Peptides Play a Role in the Immune
- Response Following Oral Infection of Mice with Toxoplasma Gondii. Eur J Microbiol
 Immunol (Bp) 2015 Sep; 5(3): 221–231
- 581 50. Sansonetti PJ, Arondel J, Huerre M, Harada A, and Matsusima K. Interleukin-8 Controls
- 582Bacterial Transpithelial Translocation at the Cost of Epithelial Destruction in Experimental
- 583 Shigellosis. Infect Immun. 1999 Mar; 67(3): 1471–1480.
- 584 51. Playford RJ, Macdonald CE, Johnson WS. Colostrum and milk-derived peptide growth 585 factors for the treatment of gastrointestinal disorders. Am J Clin Nutr. 2000 Jul;72(1):5-14.
- 586 52. Playford RJ, Hanby AM, Gschmeissner S, Peiffer LP *et al.*, The epidermal growth factor
- 587 receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in
- the human gastrointestinal tract. Gut. 1996 Aug;39(2):262-6.
- 589 53. Okuyama H, Urao M, Lee D, Drongowski RA, Coran AG. The effect of epidermal growth
- factor on bacterial translocation in newborn rabbits. J Pediatr Surg. 1998 Feb;33(2):225-8.

- 591 54. Lu L, Li T, Williams G, Petit E, Borowsky M, Walker WA. Hydrocortisone induces changes in
- gene expression and differentiation in immature human enterocytes. Am J Physiol
 Gastrointest Liver Physiol. 2011 Mar;300(3): G425-32.
- 594 55. Tian JQ, Göke M, Podolsky DK. Glucocorticoids have pleiotropic effects on small intestinal
- 595 crypt cells. Am J Physiol. 1999 Nov;277(5 Pt 1): G1027-40
- 596 56. Friedman J. The long road to leptin. J Clin Invest. 2016 Dec 1;126(12):4727-4734.
- 597 57. Cunningham KE, Turner JR. Myosin light chain kinase: pulling the strings of epithelial tight
 598 junction function. Ann N Y Acad Sci. 2012 Jul; 1258:34-42.
- 599 58. Herbert DR, Yang JQ, Hogan SP, Groschwitz K et al., Intestinal epithelial cell secretion of
- RELM-beta protects against gastrointestinal worm infection. J Exp Med. 2009 Dec21;206(13):2947-57
- 59. Barrera GJ, Tortolero GS. Trefoil factor 3 (TFF3) from human breast milk activates PAR-2
- 603 receptors, of the intestinal epithelial cells HT-29, regulating cytokines and defensins. Bratisl

604 Lek Listy. 20 Infect Immun. 2008 Feb;76(2):796-811.

- 605 60. Kozakova H, Hanson LA, Stepankova R, Kahu H, Dahlgren UI, Wiedermann U. Vitamin A
- deficiency leads to severe functional disturbance of the intestinal epithelium enzymes
 associated with diarrhoea and increased bacterial translocation in gnotobiotic rats.
 Microbes Infect. 2003 Apr;5(5):405-11.
- 609 61. Reeves PG, Briske-Anderson M, Johnson L. Pre-treatment of Caco-2 cells with zinc during
 610 the differentiation phase alters the kinetics of zinc uptake and transport (2). J Nutr
 611 Biochem. 2001 Dec;12(12):674-684.
- 612 62. Wang X, Valenzano MC, Mercado JM, Zurbach EP, Mullin JM. Zinc supplementation
 613 modifies tight junctions and alters barrier function of CACO-2 human intestinal epithelial
 614 layers. Dig Dis Sci. 2013 Jan;58(1):77-87.

615 Acknowledgements

- 616 We gratefully acknowledge funding from Barts & The London Charity, and David Wareham
- 617 (Blizard Institute, Barts and The London School of Medicine, UK) for a gift of *E. coli* K12.
- 618
- 619 *Pharmacological therapies.*

Therapy	Concentration(s) tested	Incubation Time	Reference
Colostrum	160mg/ml		51
Human epidermal growth factor (EGF)	100 & 200 ng/ml		52,53
Hydrocortisone	20,30 & 50µg/ml		54
Resistin-like molecule β (RELMβ)	100nM	-	58
		Added to Caco2 cells at	preliminary
		same time as infection	unpublished data
Trefoil Factor 3 (TFF3)	10ng/well	-	59
Colostrum + hEGF	Colostrum – 160mg/ml		51,54,55
+TFF3	hEGF – 200ng/ml		
	TFF3 – 10ng		
Vitamin A (Retinoic acid)	1, 10 & 100 µmol		60
Leptin	10µM	Pre-treated Caco2 cells	55,56
		30mins prior infection	
Myosin-light chain kinase (MLCK)	50μΜ	Pre-treated Caco2 cells 2h	32, 57
inhibitor ML-7		prior infection	
Zinc	50 & 100μM	Pre-treated Caco2 cells	61,62
		24h or 7days prior	
		infection	

620 **Table 1**: Therapeutic molecules tested including concentrations used and incubation conditions.

621 Figure Legends

622 Figure 1: Selected enteropathogens modulate barrier integrity leading to bacterial 623 translocation in vitro. Polarised Caco2 cells grown on Transwell inserts were infected with 624 Enteropathogenic Escherichia coli (EPEC), Citrobacter rodentium (C. rodentium), Cryptosporidium 625 parvum (C. parvum) or Escherichia coli K12 for 24h, with or without fetal calf serum (FCS) to model 626 nutrient-rich or nutrient-deplete conditions respectively. During the C. parvum incubations, 627 addition of Escherichia coli K12 (K12) was used as a marker of passive translocation. (A) Trans-628 epithelial resistance (TER) was measured to establish membrane integrity; n=50. One-way 629 ANOVA with the Kruskal-Wallis test was performed separately for each stimulus with or without 630 (w/o) FCS. Non-infected Caco2 cells (no infection) was used as the control and compared to each pathogen dataset: ****p<0.000.1, *** p=0.0007 and ns= non-significant. (B) Basal media from 631 632 beneath the monolayer of Caco2 cells (Transwell inserts) were cultured to measure bacterial 633 translocation (CFU/ml) from the *in vitro* model; n=50. One-way ANOVA with the Kruskal-Wallis 634 test was performed separately on samples with or without (w/o) FCS. Caco2 cells with no 635 infection were used as the control and compared to the datasets of each pathogen: *** 636 p=0.0003, ****p<0.0001, , ns = non-significant.

637

Figure 2: Enteropathogens dysregulate the expression of the tight junction protein, Claudin-4. (A) Enteropathogenic *Escherichia coli* (EPEC), *Citrobacter rodentium* (*C. rodentium*) or *Cryptosporidium parvum* (*C. parvum*) were added to non-polarised Caco2 cells grown on coverslips for 24h. Cells were then fixed, and immunofluorescence staining for claudin-4 (green) performed. Bacteria (red) were labelled with rhodamine B isothiocyanate (588nm) whilst *C. parvum* was identified using the lectin VVL-biotin and CY3-streptavidin (red; 565nm). Cell nuclei (blue) were stained using DAPI (405nm). Composite images are shown, and scale bars represent

645 100μm. (B) A representative confocal image of EPEC infection in Caco2 cells; solid arrows indicate 646 bacterial colonies and the dotted arrow highlights interruption of Claudin-4 expression. (C) 647 Western blotting of Claudin-4 protein expression (22kDa) in cells infected for 24h. A positive 648 control of recombinant claudin-4 (49kDa) was used with levels of GAPDH (36kDa) used to confirm 649 equal protein loading. D) densitometry confirmed the Western blotting *p<0.005 E) LDH assay 650 on supernatants of infected monolayers confirmed non-significant (ns) cell lysis compared to the 651 control (non-infected Caco2 cells). n=24.

652

653 Figure 3: Selected pharmacological agents impede enteropathogen-induced barrier damage 654 and subsequent bacterial translocation. (A) Transepithelial resistance (TER) of polarised Caco2 655 cells was measured after 24h infection with Enteropathogenic Escherichia coli (EPEC), Citrobacter 656 rodentium (C. rodentium) and Cryptosporidium parvum (C. parvum) together with Escherichia coli 657 K12, in the presence or absence of one of a range of potential therapeutic molecules. 24h prior 658 to infection Caco2 cells were incubated with or without fetal calf serum (FCS) to model nutrient-659 rich or nutrient-deplete conditions respectively. The TER results are presented as a percentage 660 change from Caco2 cells infected with each specific enteropathogen and no molecule. The Mann-661 Whitney U-test was performed to compare differences between nutrient deplete and nutrient 662 replete conditions; n=6, *p<0.05, **p<0.005 (B) Bacterial isolation (CFU/ml) from the basal 663 medium beneath Caco2 cell monolayers (Transwell inserts) was measured to demonstrate 664 bacterial translocation. CFU results are presented as a percentage change from Caco2 cells 665 infected with the pathogen alone and without a molecule. Differences between nutrient deplete 666 and nutrient replete conditions were tested using the Mann-Whitney U- test.; n=6, *p<0.05, 667 **p<0.005

668

Figure 4: The contra-pathogenic molecules have limited antimicrobial activity. The enteropathogens A) EPEC, B) *C. rodentium* and C) *C. parvum* + *E. coli* K12 were incubated with each potential therapeutic molecule for 24h and cultured, to establish direct killing effects of the molecules on the bacteria and presented as CFU/ml [Log₁₀]. The Mann-Whitney U-test was performed to compare each dataset with each pathogen(s) incubated in medium alone (control). n= 4; *p<0.02.

675

676 Figure 5: Trefoil factor-3 (TFF3) and the MLCK inhibitor ML-7, ameliorate dysregulation of 677 Claudin-4 expression after enteropathogen infection. (A) TFF3 and (C) ML-7 were added to 678 polarised Caco2 cells prior to infection with Enteropathogenic Escherichia coli (EPEC), Citrobacter 679 rodentium (C. rodentium) or Cryptosporidium parvum (C. parvum). After 24h, cells were lysed to 680 measure protein levels of Claudin-4 (22kDa) by Western blotting, with recombinant claudin-4 681 (49kDa) used as a positive control. Levels of GAPDH (36kDa) were also determined to confirm 682 equal protein loading. B) TFF3 and D) ML7, represent densitometry of the Western blots *p<0.05, 683 **P<0.005, ****P<0.0001. E) supernatants of infected monolayers co-stimulated with TFF3 or 684 ML7 were tested for cell cytotoxicity using the LDH assay and compared with controls (infection 685 + no molecule) using One-way ANOVA with the Kruskal-Wallis test. n=12; *p<0.05, **p<0.005, ***p<0.005. 686

687

Figure 6: TFF3 improves transepithelial resistance and reduces bacterial translocation in a dosedependent manner, demonstrating the reciprocal relationship between them. Transepithelial resistance (TER) and bacterial translocation (BT; CFU/mI) were measured in experiments with varying concentrations of TFF3 during Enteropathogenic *Escherichia coli* (EPEC; A and B) and *Citrobacter rodentium* (CR; C and D) infections for 24h. The experiments were conducted in the 693 presence (A and C) or absence (B and D) of fetal calf serum (FCS) to model nutrient-rich or 694 nutrient-deplete conditions respectively. TFF3 concentrations were Ong/ml (red), 5ng/ml (green), 695 10ng/ml (blue) or 20ng/ml (brown). Spearman's rank correlation coefficient demonstrates ρ = -696 0.80 (P<0.0001) for EPEC and ρ = -0.66 (P<0.0001) for *C. rodentium*. 697 698 Figure 7: Trefoil factor-3 (TFF3) and Relm-β increase both pro- and anti-inflammatory cytokine 699 production. Polarised Caco2 cells were infected with: Enteropathogenic Escherichia coli (EPEC), 700 Citrobacter rodentium (CR) and Cryptosporidium parvum (CP) and co-stimulated with TFF3 or 701 Relm-β for 24h in nutrient (FCS) deprived conditions. The supernatant from the cells were used 702 to measure a range of cytokines and chemokines. n=6. One-way ANOVA with Tukey's post hoc 703 was used for analysis. *p=0.01, **p=0.002, ***p<0.001. LLOD= Lowest level of detection.

Supplementary Material

Therapy	Rationale	Reference
Colostrum	The first milk produced after birth, rich in bioactive molecules including growth	51
	factors. Colostral fractions or individual peptides present in colostrum have been	
	shown to be beneficial in the treatment of gastrointestinal conditions such as	
	inflammatory bowel disease and so could limit enteropathogen-induced epithelial	
	barrier damage.	
Human epidermal	A component of human colostrum (200µg/L) and milk (30-50µg/L). EGF receptors	52,53
growth factor	are present on the basolateral membrane of enterocytes. Luminal EGF may gain	
(EGF)	access to the basolateral receptors in the immature neonatal gut due to increased	
	permeability, or in any enteropathy characterised by increased permeability to	
	macromolecules.	
Hydrocortisone	The glucocorticoid hydrocortisone is present in breast milk. It has anti-	54
	inflammatory properties in both rat and human studies, has been shown to	
	regulate the expression of genes involved in development of cell polarity, tight	
	junction formation and interactions with extracellular matrices and so may assist	
	in maintaining epithelial cell integrity after enteropathogen-induced epithelial	
	barrier damage	
Leptin	Leptin is an adipose-tissue derived hormone that functions in maintaining	55,56
	homeostatic control of adipose tissue mass and so its levels fall during starvation.	
	Leptin exerts pleiotropic effects on the intestinal epithelium including nutrient	
	absorption, epithelial growth, inflammation and injury. It contributes to the	
	defence against intestinal amoebiasis. Therefore, leptin could protect the	
	intestinal epithelium against pathogens directly or indirectly.	
Myosin-light chain	MLCK induces contraction of the peri-junctional actomyosin ring through myosin II	32,57
kinase (MLCK)	regulatory light chain phosphorylation which regulates tight junction permeability.	
inhibitor ML-7	EPEC infection has been shown to induce phosphorylation of the 20 kilodalton	
	myosin light chain (MLC) in the intestinal epithelium, which causes changes in	

	intestinal barrier function, contributing to the diarrhoea associated with the	
	infection. However, Inhibition of the MLC20 phosphorylation prevented EPEC	
	induced changes to the epithelium. Therefore, ML-7 could be a class of targeted	
	therapeutic agents that restore barrier function in intestinal disease states.	
Resistin-like	Resistin-like molecule (RELM) beta is secreted by goblets cells in the intestine and	46,47,58
molecule β	are essential for normal spontaneous expulsion and IL-4-induced expulsion of	
(RELMβ)	parasitic helminths, which live in the intestinal lumen but not in IECs. It is strongly	
	induced within goblet cells during C. rodentium infection. It appears also to act as	
	a CD4+T cell chemoattractant in the colon, in part via the induction of increased	
	IEC proliferation. Therefore, the molecule could induce an immunomodulatory	
	response towards the enteropathogens, maintaining epithelial barrier integrity.	
Trefoil Factor 3	Trefoil peptides are also present in breast milk and in goblet cells along the	59
(TFF3)	intestinal tract. Goblet cells are depleted during infection with C. rodentium and	
	EPEC which results in dramatically reduced TFF3 levels. TFF3 has been shown to	
	down-regulate cytokines (IL-8 & IL-6) and promote the expression of the	
	antimicrobial peptides, beta defensin (hBD2&4) in enterocytes. They have been	
	shown to be activated in intestinal cells through protease activated receptors 2	
	(PAR-2) and so increased TFF3 levels during enteropathogen infections may	
	improve the intestinal epithelium.	
Vitamin A	Vitamin A and its analogs are essential for normal development. Vitamin A	60
(Retinoic acid)	deficiency (VAD) is associated with decreased immune response and increased	
	bacterial translocation and mortality e.g. the retinoic acid (RA) receptor α (RAR α)	
	signaling in intestinal epithelial cells (IECs) deregulates epithelial lineage	
	specification, leading to reduced luminal bacterial detection (for C. rodentium).	
	Therefore, increases in Vitamin A exposure could reduce bacterial translocation	
Zinc	Zinc is an essential nutrient. Its deficiency is known to result in epithelial barrier	61,62
	leak in the intestines and alter TJ composition. Zinc oxide (ZnO) has a protective	

effect in pigs suffering from enterotoxigenic Escherichia coli (ETEC) infections. This	
observation may be extended to enteropathogens-induced epithelial damage.	

706 **Supplementary Table 1: Molecules tested and rationale for selection**

- 707
- 708 Assessment of Bacterial Adherence
- 709 Cells grown on coverslips were infected with EPEC, C. rodentium or C. parvum + E. coli K12 for 0,

710 15, 30, 60 and 120min. Medium was then removed, cells washed with PBS and fixed in methanol

711 (VWR, Leicestershire, UK) for 15min followed by overnight Giemsa (VWR, Leicestershire, UK)

- staining. Numbers of cells and bacteria were counted at x200 magnification in 20 randomly
- selected fields under a Leica DM500 upright Epi-fluorescent Dual Camera.
- 714


715 Bacterial Invasion Assay

Cells were infected on the apical side with EPEC, *C. rodentium* or *C. parvum* + *E. coli* K12, for 0, 15, 30, 60 or 120min. Cells were washed in culture media and incubated with gentamicin (200ug/ml) for 60min to kill extracellular bacteria. Cells were washed three times and lysed in 10mM Tris-HCL pH7.5, 1mM EDTA, and 1% Triton-X (Sigma-Aldrich Company Ltd, Dorset, UK) prior to culture.

- 721
- 722
- 723
- 724
- 725

726





Supplementary Figure 1: EPEC (rabbit), *C. rodentium* (murine) and *C. parvum* + *E. coli* K12 (human) attach and infect Caco2 cells. Enteropathogenic *Escherichia coli* (EPEC), *Citrobacter rodentium* (*C. rodentium*) or *Cryptosporidium parvum* (*C. parvum*) together with *Escherichia coli K12* (*K12*) were incubated with Caco2 cell monolayers for 0, 15, 30, 60 and 120min. Cells were washed and underwent Giemsa staining a) The number of bacteria attached per cell was then enumerated in 20 fields for the adhesion assay b) infected cells were treated with gentamicin for 1h to kill only the extracellular pathogens. The Caco2 cells counted then lysed and cultured on

Luria-Bertani (LB) agar plates to enumerate the number of viable intracellular bacteria per Caco2
cell over the time course. Statistical testing using One-way ANOVA with the Kruskal-Wallis test
was used to compare the infections with the no-infection control at each time point; *P<0.05,
**p=0.006.